Daydrop Triple Action for Allergic Eye Symptoms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective post-market investigation uses a quasi-experimental before-and-after design with intra-subject control to assess safety and efficacy over 14 days in adults with active allergic conjunctivitis. Participants use the Daydrop formulation containing ectoine, hyaluronic acid, and carboxymethylcellulose once or twice daily, as determined by the investigator. Primary efficacy focuses on reduction in ocular itching, while primary safety looks at serious adverse events, with assessments at baseline, 24 hours, 7 days, and 14 days. Secondary outcomes and full methodology details are not provided in the brief.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years or older
* Active episode of allergic conjunctivitis prior to study initiation, assessed and confirmed by the specialist using a slit-lamp examination.
* Score of ≥ 2 points on either the Ora Calibra Ocular Itching Score or the Ocular Redness Score, as assessed by the participant and the investigator, respectively.
* Ability to self-administer the study product.
* Ability to understand the Patient Information Sheet and provide written informed consent.

Exclusion Criteria:

* History of hypersensitivity to any component of the study product.
* Systemic treatment with antihistamines (e.g., loratadine, cetirizine, desloratadine, ebastine) or corticosteroids (e.g., fluorometholone, loteprednol, dexamethasone), and/or topical treatment with any ophthalmic medication with anti-allergic or anti-inflammatory activity, including antihistamines or mast cell stabilizers (e.g., olopatadine, ketotifen, azelastine) and ophthalmic corticosteroids (e.g., fluorometholone, loteprednol, dexamethasone), except for artificial tears, within the week prior to study initiation.
* Clinically significant ocular infection or inflammation.
* Other active ocular conditions, including but not limited to glaucoma, Sjögren's syndrome, severe dry eye disease, Stevens-Johnson syndrome, active uveitis or keratitis, severe or chronic blepharitis, and other forms of conjunctivitis of non-allergic origin.
* Ocular surgery within the 3 months prior to study entry.
* Refractive surgery within the previous 6 months.
* Pregnancy or planned breastfeeding.

Where it's running

• Complutense Medical Center (Virtus Group)
  Madrid, Madrid, Spain Recruiting

Study contacts

• Study coordinator: Josune Torrecilla
• Email: jtorrecilla@imasmed.com
• Phone: +34945561134

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oral Kelulut honey to help itchy, red, watery and dry eyes from allergic conjunctivitis

  This trial will see if adults with allergic conjunctivitis who take daily oral Kelulut honey for one month have less itchy, red, watery eyes and dry eye symptoms than people taking a honey‑flavored placebo, and it will monitor side effects.

  Recruiting Universiti Sains Malaysia · Kota Bharu, Kelantan · NCT07273747

• SUBMO for Submucosal Injection in Endoscopic Resection of Colorectal Polyps

  This trial tests whether SUBMO®, a hyaluronic acid-based gel with blue dye, can safely and effectively replace saline for submucosal injection during endoscopic removal of colorectal polyps larger than 10 mm.

  Recruiting at 4 sites i+Med S.Coop. · Barcelona, Barcelona and 3 other locations · NCT07448129

• BtH Body 2.2% for shaping and plumping large body areas

  This study tests BtH Body 2.2% injections to see if it safely improves volume and contour in the glutes, thighs, or abdomen for adults seeking aesthetic enhancement.

  Recruiting i+Med S.Coop. · Madrid, Madrid · NCT07441135

• ZKARE® gel with ZKAPI® applicator for treating chronic ulcers

  This trial will try adding ZKARE® gel applied with the ZKAPI® applicator to standard wound care to see if it helps heal chronic pressure, diabetic foot, and venous leg ulcers faster and safer.

  Recruiting i+Med S.Coop. · Vitoria-Gasteiz, Álava · NCT07406152

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.